NTRA Stock Price Today (October 2026) — Natera, Inc. Analysis & Key Metrics 2026-10-20
Natera, Inc. (NTRA) is trading at $405.92, up 1.63% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $403.89 (0.5% downside).
- Volatility is moderate (32.77% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (37.70% YoY) alongside competitive pressures in the Diagnostics & Research space.
NTRA Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Natera, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $57.66B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
-0.5% downside from target
Key Investor Questions About NTRA
What investors need to know before buying
Based on current market data, NTRA presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 59.32)
- Fundamentals say: Looking solid (debt and growth supportive)
NTRA's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NTRA investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $238.49M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, NTRA stock traded between $178.01 and $437.41 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 32.77% annualized volatility and β=1.16, the stock exhibits high sensitivity to market moves—making NTRA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Natera (NTRA) Is Expanding Cancer Testing Rapidly. Does Its Valuation Leave Room for Error?
Should You Be Worried About Tempus AI Stock?
Why Natera (NTRA) Stock Is Up Today
Natera Insider Sold Shares Worth $20,132,028, According to a Recent SEC Filing
Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
Latest TickZen Insights
All insights →No TickZen article on NTRA yet. Our newest analysis:
Explore More Analysis for NTRA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 11, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Natera, Inc.
Natera, Inc. (NTRA) is currently trading at $405.92. The RSI (14-day) is at 59.3, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $403.89 implies 0.5% downside from current levels. Volatility is moderate at 32.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Natera, Inc. (NTRA): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 26.95. Price-to-Sales is 18.20. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering NTRA, the consensus price target is $403.89. This represents a 0.5% downside from the current price of $405.92. The range spans from a low target of $280.00 to a high target of $490.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Natera, Inc. (NTRA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Natera, Inc. (NTRA) investors include: 1. Moderate volatility (32.8% annualized)—price swings are notable. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Natera, Inc.'s (NTRA) current debt and financial health profile: Total debt stands at $238.49M. The debt-to-equity ratio is 0.13x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.00, indicating strong short-term liquidity. The quick ratio is 2.74. The company holds $1.09B in cash and equivalents. Free cash flow is positive at $104.03M, providing a cushion for debt servicing and shareholder returns.